| Bioactivity | SB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist (pKi =9.4 and 9.5 at the OX1 and OX2 receptor, respectively). | ||||||||||||
| Target | pKi: 9.4 (OX1), 9.5 (OX2) | ||||||||||||
| Invitro | SB-649868 is identified as one the most in vitro potent dual OX1 and OX2 receptor antagonist known at that time (pKi=9.4 and 9.5 at the OX1 and OX2 receptor, respectively) [1]. SB-649868 antagonizes orexin-A-induced inositol 1 phosphate (IP1) accumulation with the following pKB value (OX1=9.67; OX2=9.64). SB-649868 displaces the [3H]ACT-078573 receptor binding with the following pKi values: OX1=9.27; OX2=8.91. Increasing concentrations of SB-649868 (0.3 nM-30 nM) induces a rightward shift of the orexin-A CRCs with a depression of the agonist efficacy suggesting a clear non-surmountable behavior. The calculated apparent pKb values are 9.67±0.03 and 9.64±0.07 for OX1 and OX2[2]. | ||||||||||||
| Name | SB-649868 | ||||||||||||
| CAS | 380899-24-1 | ||||||||||||
| Formula | C26H24FN3O3S | ||||||||||||
| Molar Mass | 477.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Di Fabio R, et al. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2receptor antagonist useful for treatment of sleep disorders. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5562-7. [2]. Faedo S, et al. Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptorantagonists. Eur J Pharmacol. 2012 Oct 5;692(1-3):1-9. |
SB-649868
CAS: 380899-24-1 F: C26H24FN3O3S W: 477.55
SB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist(pKi =9.4 and 9.5 at the OX1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.